Why VCs are playing the royalty game; Canada approves Jetrea;

@FierceBiotech: We're looking for the fiercest women in biotech for our 2013 report. Editor's note | Nomination form | Follow @FierceBiotech

@JohnCFierce: MannKind rewarded for positive Afrezza data with $40M financing. Report | Follow @JohnCFierce

@RyanMFierce: Scientists found a causal link between a tooth cavity bacterium and colon cancer in mice, potential drug target. More from TheScientist | Follow @RyanMFierce

@EmilyMFierce: SeattleBioMed wins $16M NIH grant for tuberculosis research. ICYMI yesterday from FierceBiotechResearch.com | Follow @EmilyMFierce

> The InVivo Blog analyzed the unlikely role of a pair of VC firms, Clarus and Aisling, in the purchase of royalty rights from Quest Diagnostics for Johnson & Johnson's ($JNJ) and Pharmacylics' potential blockbuster leukemia drug ibrutinib. Blog

> Health Canada has approved Jetrea from ThromboGenics and Alcon for symptomatic vitreomacular adhesion. Release

Medical Device News

@FierceMedDev: UPDATED: Bard ordered to pay $2M in vaginal mesh trial defeat. News | Follow @FierceMedDev

@DamianFierce: A global cybersecurity outfit is lending a hand to the medical device industry. Article | Follow @DamianFierce

@MarkHFierce: Heathrow Airport have been warned that female terrorists might strike with breast implant explosives. Report | Follow @MarkHFierce

@MichaelGFierce: ICYMI: St. Jude nets FDA approval for low-radiation ablation catheters. Article | Follow @MichaelGFierce

> China targets medical device misuse. Item

> Coloplast feels weight of rival's vaginal mesh legal woes. Story

> Gene By Gene joins Ambry to fight Myriad's Dx 'monopoly.' Report

Pharma News

@FiercePharma: Trending online: Which are pharma's top 4 innovators? Hint: It's not the big guys. More | Follow @FiercePharma

@EricPFierce: FDA wants help figuring out how to stop addicts from getting to the APIs in opioid painkillers. Story from FiercePharmaManufacturing.com | Follow @EricPFierce

@CarlyHFierce: The latest in India vs. Big Pharma IP developments: Roche won't pursue Herceptin patents in India. Article | Follow @CarlyHFierce

> NICE denies Pfizer lung cancer drug in final guidance. Report

> Stada quickly pulls off deal for OTC maker Thorton & Ross. Article

> Easing U.S. drug spending gives Sanofi, Novo room to raise insulin prices. Story

And Finally… Scientists reported causal links between a mouth microbe and colon cancer. Article

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.